DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients

By Rieck Mariana   Schumacher-Schuh Artur F   Altmann Vivian   Francisconi Carolina LM   Fagundes Paulo TB   Monte Thaís L   Callegari-Jacques Sidia M   Rieder Carlos RM   Hutz Mara H  

Pharmacogenomics, Vol. 13, Iss. 15, 2012-11 ,pp. : 1701-1710

Future Medicine

Access to resources Recommend Favorite

The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson’s disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram

By Kuan Wei-Li   Zhao Jing-Wei   Barker Roger  

Psychopharmacology, Vol. 197, Iss. 2, 2008-04 ,pp. : 279-293

Springer Publishing Company

Access to resources Recommend Favorite

Manage levodopa-induced motor complications in patients with Parkinson's disease with careful selection of other antiparkinsonian agents

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 24, Iss. 1, 2008-01 ,pp. : 17-21

Adis International

Access to resources Recommend Favorite

Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease

By Müller Thomas  

Expert Review of Neurotherapeutics, Vol. 13, Iss. 6, 2013-06 ,pp. : 707-718

Informa Healthcare

Access to resources Recommend Favorite

Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson’s disease in the MPTP-induced mice model

By Xiang Yu   Wu Qian   Liang Liang   Wang Xueqing   Wang Jiancheng   Zhang Xuan   Pu Xiaoping   Zhang Qiang  

Journal of Drug Targeting, Vol. 20, Iss. 1, 2012-01 ,pp. : 67-75

Informa Healthcare

Access to resources Recommend Favorite